Cargando…
Multiparameter Evaluation of the Platelet-Inhibitory Effects of Tyrosine Kinase Inhibitors Used for Cancer Treatment
Current antiplatelet drugs for the treatment of arterial thrombosis often coincide with increased bleeding risk. Several tyrosine kinase inhibitors (TKIs) for cancer treatment inhibit platelet function, with minor reported bleeding symptoms. The aim of this study was to compare the antiplatelet prop...
Autores principales: | Tullemans, Bibian M. E., Veninga, Alicia, Fernandez, Delia I., Aarts, Maureen J. B., Eble, Johannes A., van der Meijden, Paola E. J., Heemskerk, Johan W. M., Kuijpers, Marijke J. E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8540269/ https://www.ncbi.nlm.nih.gov/pubmed/34681859 http://dx.doi.org/10.3390/ijms222011199 |
Ejemplares similares
-
Tyrosine Kinase Inhibitor Pazopanib Inhibits Platelet Procoagulant Activity in Renal Cell Carcinoma Patients
por: Tullemans, Bibian M. E., et al.
Publicado: (2018) -
Effects of Platelet Agonists and Priming on the Formation of Platelet Populations
por: Veninga, Alicia, et al.
Publicado: (2021) -
Galectin-1 and platelet factor 4 (CXCL4) induce complementary platelet responses in vitro
por: Dickhout, Annemiek, et al.
Publicado: (2021) -
Ultra-high-throughput Ca(2+) assay in platelets to distinguish ITAM-linked and G-protein-coupled receptor activation
por: Fernández, Delia I., et al.
Publicado: (2021) -
GPVI expression is linked to platelet size, age, and reactivity
por: Veninga, Alicia, et al.
Publicado: (2022)